Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy

  • Sofie Van Binnebeek
  • Kristof Baete
  • Bert Vanbilloen
  • Christelle Terwinghe
  • Michel Koole
  • Felix M. Mottaghy
  • Paul M. Clement
  • Luc Mortelmans
  • Karin Haustermans
  • Eric Van Cutsem
  • Alfons Verbruggen
  • Kris Bogaerts
  • Chris Verslype
  • Christophe M. Deroose
Original Article



Assessment of kidney function evolution after 90Y-DOTATOC peptide receptor radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold of biological effective dose (BED) to the kidney.


In a prospective phase II study, patients with metastasized neuroendocrine tumours were evaluated for therapy using 185 MBq 111In-pentetreotide with amino acid coinfusion. Planar whole-body images were acquired at four time-points after injection and kidney volumes were measured using CT/MRI. BED to the kidneys was estimated using an extended BED formula and biexponential renal clearance. Based on published BED dose–toxicity relationships, we allowed a maximal kidney BED of 37 Gy; if the calculated BED exceeded 37 Gy, treatment activity was reduced accordingly. Kidney function was assessed at baseline and at 18 months, predominantly using 51Cr-EDTA. The rate of renal function decline was expressed as annual glomerular filtration rate loss (aGFRL).


Only 22 of 50 patients reached the 18-months time-point, with most missing patients having died due to disease progression. In the 22 patients who reached 18 months, no rapid kidney function deterioration was observed over the 18 months, aGFRL >33 % was not seen, and only three patients showed an increase of one toxicity grade and one patient an increase of two grades. No significant correlations between kidney volume (p = 0.35), baseline GFR (p = 0.18), risk factors for renal function loss (p = 0.74) and aGFRL were observed. Among the 28 patients who did not reach 18 months, one developed grade 4 kidney toxicity at 15 months after PRRT.


Prospective dosimetry using a 37 Gy BED as the threshold for kidney toxicity is a good guide for 90Y-DOTATOC PRRT and is associated with a low risk of rapid renal function deterioration and evolution to severe nephrotoxicity.


PRRT Dosimetry Renal function 90Y-DOTATOC 



The project was funded by Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT) ( with grant “Innovatie door Wetenschap en Technologie-Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit project no. 0707181”. S.V.B. is a beneficiary of an Emmanuel van der Schueren grant of the Vlaamse Liga tegen Kanker. C.M.D. is a postdoctoral fellow of the Clinical Research Fund of the UZ Leuven. This study was partially funded within the framework of ORAMED for which funding was received from the European Community’s Seventh Framework Program (FP7/2007/2011) under grant agreement no. 211361.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

259_2013_2670_MOESM1_ESM.docx (196 kb)
ESM 1 (DOCX 195 kb)


  1. 1.
    Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72. doi: 10.1016/S1470-2045(07)70410-2.PubMedCrossRefGoogle Scholar
  2. 2.
    Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med. 2002;43:610–6.PubMedGoogle Scholar
  3. 3.
    Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23. doi: 10.1200/JCO.2010.33.7873.PubMedCrossRefGoogle Scholar
  4. 4.
    Bushnell Jr DL, O’Dorisio TM, O’Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652–9. doi: 10.1200/JCO.2009.22.8585.PubMedCrossRefGoogle Scholar
  5. 5.
    Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30. doi: 10.1200/JCO.2007.15.2553.PubMedCrossRefGoogle Scholar
  6. 6.
    Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35. doi: 10.1007/s00259-011-1902-1.PubMedCrossRefGoogle Scholar
  7. 7.
    Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:92S–8.Google Scholar
  8. 8.
    Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207–16. doi: 10.1007/s00259-002-1023-y.PubMedCrossRefGoogle Scholar
  9. 9.
    de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med. 2002;43:617–20.PubMedGoogle Scholar
  10. 10.
    Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56. doi: 10.1007/s00259-008-0778-1.PubMedCrossRefGoogle Scholar
  11. 11.
    Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-D-Phe1–Tyr3-octreotide (SMT487) – a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510–8. doi: 10.1007/s00259-003-1117-1.PubMedCrossRefGoogle Scholar
  12. 12.
    Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46 Suppl 1:83S–91.PubMedGoogle Scholar
  13. 13.
    Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552–4. doi: 10.1007/s002590100599.PubMedCrossRefGoogle Scholar
  15. 15.
    Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Stoffel MP, Pollok M, Fries J, Baldamus CA. Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma. Nephrol Dial Transplant. 2001;16:1082–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46 Suppl 1:99S–106.PubMedGoogle Scholar
  19. 19.
    Van Binnebeek S, Deroose CM, Baete K, Terwinghe C, Vanbilloen B, Koole M, et al. Altered biodistribution of somatostatin analogues after first cycle of peptide receptor radionuclide therapy. J Clin Oncol. 2011;29:e579–81. doi: 10.1200/JCO.2010.34.3384.PubMedCrossRefGoogle Scholar
  20. 20.
    Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303–11.PubMedGoogle Scholar
  21. 21.
    Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467–75.PubMedGoogle Scholar
  22. 22.
    Förster GJ, Engelbach MJ, Brockmann JJ, Reber HJ, Buchholz HG, Macke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med. 2001;28:1743–50. doi: 10.1007/s002590100628.PubMedCrossRefGoogle Scholar
  23. 23.
    Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386–92. doi: 10.1007/s00259-004-1561-6.PubMedCrossRefGoogle Scholar
  24. 24.
    Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMedGoogle Scholar
  25. 25.
    Van Binnebeek S, Baete K, Terwinghe C, Vanbilloen B, Haustermans K, Mortelmans L, et al. Significant impact of transient deterioration of renal function on dosimetry in PRRT. Ann Nucl Med. 2013;27:74–7. doi: 10.1007/s12149-012-0651-y.PubMedCrossRefGoogle Scholar
  26. 26.
    Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35:1123–34.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44:1113–47.PubMedGoogle Scholar
  28. 28.
    Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response – implications for radionuclide therapy. J Nucl Med. 2008;49:1884–99.PubMedCrossRefGoogle Scholar
  29. 29.
    Thames HD. A new model of proliferative response to fractionated irradiation. Radiother Oncol. 1988;13:311–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA0, Tyr3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18:619–25. doi: 10.1089/108497803322287718.PubMedCrossRefGoogle Scholar
  31. 31.
    Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–72. doi: 10.1373/clinchem.2006.077180.PubMedCrossRefGoogle Scholar
  32. 32.
    Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.PubMedCrossRefGoogle Scholar
  35. 35.
    Romer A, Seiler D, Marincek N, Brunner P, Koller MT, Ng QK, et al. Somatostatin-based radiopeptide therapy with [Lu-DOTA]-TOC versus [Y-DOTA]-TOC in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013. doi: 10.1007/s00259-013-2559-8.
  36. 36.
    Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–22. doi: 10.1007/s00259-002-1050-8.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62. doi: 10.1200/JCO.2005.08.066.PubMedCrossRefGoogle Scholar
  38. 38.
    Fabbri C, Sarti G, Cremonesi M, Ferrari M, Di Dia A, Agostini M, et al. Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm. 2009;24:145–54. doi: 10.1089/cbr.2008.0543.PubMedCrossRefGoogle Scholar
  39. 39.
    Lhommel R, van Elmbt L, Goffette P, Van den Eynde M, Jamar F, Pauwels S, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging. 2010;37:1654–62. doi: 10.1007/s00259-010-1470-9.PubMedCrossRefGoogle Scholar
  40. 40.
    D’Arienzo M, Chiaramida P, Chiacchiararelli L, Coniglio A, Cianni R, Salvatori R, et al. 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun. 2012;33:633–40. doi: 10.1097/MNM.0b013e3283524220.PubMedCrossRefGoogle Scholar
  41. 41.
    Walrand S, Jamar F, van Elmbt L, Lhommel R, Bekonde EB, Pauwels S. 4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET. J Nucl Med. 2010;51:1969–73. doi: 10.2967/jnumed.110.080093.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Sofie Van Binnebeek
    • 1
    • 2
  • Kristof Baete
    • 1
    • 2
  • Bert Vanbilloen
    • 1
    • 2
  • Christelle Terwinghe
    • 1
    • 2
  • Michel Koole
    • 3
  • Felix M. Mottaghy
    • 4
    • 5
  • Paul M. Clement
    • 6
    • 7
  • Luc Mortelmans
    • 1
    • 2
  • Karin Haustermans
    • 8
    • 9
  • Eric Van Cutsem
    • 9
    • 10
  • Alfons Verbruggen
    • 11
  • Kris Bogaerts
    • 12
  • Chris Verslype
    • 9
    • 10
  • Christophe M. Deroose
    • 1
    • 2
    • 13
  1. 1.Nuclear MedicineUniversity Hospitals LeuvenLeuvenBelgium
  2. 2.Department of Imaging & PathologyKU LeuvenLeuvenBelgium
  3. 3.Department of Nuclear MedicineUniversity Medical Centre GroningenGroningenThe Netherlands
  4. 4.Department of Nuclear MedicineUniversity Hospital AachenAachenGermany
  5. 5.Department of Nuclear MedicineMaastricht University Medical CenterMaastrichtThe Netherlands
  6. 6.Medical OncologyUniversity Hospitals LeuvenLeuvenBelgium
  7. 7.Laboratory of Experimental OncologyKU LeuvenLeuvenBelgium
  8. 8.Radiation OncologyUniversity Hospitals LeuvenLeuvenBelgium
  9. 9.Department of OncologyKU LeuvenLeuvenBelgium
  10. 10.Division of Digestive OncologyUniversity Hospitals LeuvenLeuvenBelgium
  11. 11.Laboratory for RadiopharmacyKU LeuvenLeuvenBelgium
  12. 12.Division of Public Health and Primary Care (I-Biostat)KU LeuvenLeuvenBelgium
  13. 13.Nuclear MedicineUZ LeuvenLeuvenBelgium

Personalised recommendations